Distinct MHC gene expression patterns during progression of melanoma

Abnormal expression of major histocompatibility complex (MHC) molecules in melanoma has been reported previously. However, the MHC molecule expression patterns in different growth phases of melanoma and the underlying mechanisms are not well understood. Here, we demonstrate that in vertical growth phase (VGP) melanomas, MHC genes are subject to increased rates of DNA copy number gains, accompanied by increased expression, in comparison to normal melanocytes. In contrast, MHC expression in metastatic melanomas drastically decreased compared to VGP melanomas, despite still prevalent DNA copy number gains. Subsequent investigations found that the master transactivator of MHC genes, CIITA, was also significantly downregulated in metastatic melanomas when compared to VGP melanomas. This could be one of the mechanisms accounting for the discrepancy between DNA copy number and expression level in metastatic melanomas, a potentially separate mechanism of gene regulation. These results infer a dynamic role of MHC function in melanoma progression. We propose potential mechanisms for the overexpression of MHC molecules in earlier stages of melanoma as well as for its downregulation in metastatic melanomas. © 2009 Wiley‐Liss, Inc.

[1]  K. Wright,et al.  Epigenetic regulation of MHC-II and CIITA genes. , 2006, Trends in immunology.

[2]  M. Jager,et al.  Epigenetic silencing of MHC2TA transcription in cancer. , 2006, Biochemical pharmacology.

[3]  N. Cascinelli,et al.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.

[4]  E. Shevach,et al.  Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[5]  N. Mulder,et al.  The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. , 1993, Anticancer research.

[6]  R. Salgia,et al.  MET pathway as a therapeutic target. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[8]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[9]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[10]  T. Tomonaga,et al.  Strong HLA‐DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c‐myc suppression by interferon‐γin situ , 2006, Cancer science.

[11]  B. Seliger,et al.  Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome , 2005, Clinical Cancer Research.

[12]  B. Seliger,et al.  Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. , 2006, Cancer research.

[13]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[14]  H. Kuipers,et al.  Transcriptional regulation of antigen presentation. , 2004, Current opinion in immunology.

[15]  F. Garrido,et al.  HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank , 2009, Cancer Immunology, Immunotherapy.

[16]  L. Staudt,et al.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.

[17]  F. Aoudjit,et al.  HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. , 2004, Experimental cell research.

[18]  D. Ruiter,et al.  Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. , 1988, Cancer research.

[19]  G. Pawelec,et al.  High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity , 2005, Cancer Immunology, Immunotherapy.

[20]  John Quackenbush,et al.  CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data , 2005, Bioinform..

[21]  S. Ferrone,et al.  Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. , 2006, Cancer research.

[22]  D. Schadendorf,et al.  Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines , 2007, Immunogenetics.

[23]  M. Maio,et al.  Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? , 2003, Oncogene.

[24]  Joel Greshock,et al.  High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization , 2005, Breast Cancer Research.

[25]  Vladimir Brusic,et al.  MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Wigler,et al.  Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. , 2003, Cancer cell.

[27]  B. Weber,et al.  SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant , 2004, Cancer Research.

[28]  J. M. Boss,et al.  Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[30]  G. Pawelec,et al.  Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines , 2008, Cancer Immunology, Immunotherapy.

[31]  J. Squire,et al.  Chromosome 6p amplification and cancer progression , 2006, Journal of Clinical Pathology.

[32]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[33]  B. Weber,et al.  Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma‐derived cell lines , 2009, Genes, chromosomes & cancer.

[34]  S. Ferrone,et al.  Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  S. Ferrone,et al.  Immune selective pressure and HLA class I antigen defects in malignant lesions , 2006, Cancer Immunology, Immunotherapy.

[36]  B. Peterlin,et al.  Expression of MHC II genes. , 2006, Current topics in microbiology and immunology.

[37]  H. Byers,et al.  Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. , 1998, Hematology/oncology clinics of North America.

[38]  K. Ozato,et al.  Induction of MHC class I expression by the MHC class II transactivator CIITA. , 1997, Immunity.

[39]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[40]  J. Ting,et al.  Constitutive Expression of MHC Class II Genes in Melanoma Cell Lines Results from the Transcription of Class II Transactivator Abnormally Initiated from Its B Cell-Specific Promoter1 , 2001, The Journal of Immunology.

[41]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[42]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[43]  S. Ferrone,et al.  HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. , 2006, Cancer research.

[44]  W. Reith,et al.  Regulation of MHC class II genes: lessons from a disease. , 1996, Annual review of immunology.

[45]  P. J. van den Elsen,et al.  DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. , 2003, Clinical immunology.

[46]  R. Ádány,et al.  Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. , 2001, Cytometry.

[47]  G. Fleuren,et al.  Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.